Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation

Area of Science:

• Epigenetics and Cancer Biology
• Chromatin Biology
• Molecular Oncology

Background:

• Dysregulated epigenetic states are a hallmark of cancer, often driven by genetic alterations in epigenetic regulators.
• Missense mutations in histones, key components of nucleosome core particles, are observed in cancer, but their oncogenic mechanisms remain largely unknown.
• Histone N-terminal tails play crucial roles in chromatin structure and gene regulation.

Purpose of the Study:

• To investigate the oncogenic mechanisms of cancer-associated histone mutations affecting arginines in the histone H3 N-terminal tail.
• To determine how these mutations impact chromatin domains, gene regulation, and cellular differentiation.
• To elucidate the functional consequences of these histone mutations in cancer development.

Main Methods:

• Analysis of histone H3 mutations (H3R2C, H3R26C) and their effects on chromatin.
• Assessment of H3K27me3 levels and distribution in cells expressing mutant histones.
• Functional assays using mesenchymal progenitor cells and teratomas to evaluate differentiation capacity.

Main Results:

• Cancer-associated histone H3 arginine mutations disrupt repressive chromatin domains and alter gene regulation.
• Mutations H3R2C and H3R26C lead to reduced levels of the repressive histone mark H3K27me3.
• Loss of H3K27me3 results in de-repression of differentiation pathways, and H3R26C expression impairs differentiation in cellular and in vivo models.

Conclusions:

• Cancer-associated H3 N-terminal arginine mutations reduce Polycomb Repressive Complex 2 (PRC2) activity.
• These mutations disrupt chromatin-dependent developmental functions, presenting a cancer-relevant phenotype.
• Understanding these mechanisms provides insights into histone mutations as drivers of oncogenesis.